PTC Therapeutics Inc
PTCT
26.39USD+0.11 (+0.42%)Market ClosedWatchlist
Market Summary
USD26.39+0.11
Market Closed0.42%
PTCT Alerts
PTCT Stock Price
View Fullscreen
PTCT RSI Chart
PTCT Alerts
PTCT Valuation
PTCT Price/Sales (Trailing)
PTCT Profitability
PTCT Fundamentals
PTCT Revenue
PTCT Earnings
Price Action
Last 7 days
10%
Last 30 days
34.6%
Last 90 days
-35.6%
Trailing 12 Months
-31.1%
How does PTCT drawdown profile look like?
PTCT Financial Health
PTCT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 770.4M | 818.7M | 798.2M | 0 |
| 2022 | 569.4M | 618.2M | 696.6M | 698.8M |
| 2021 | 430.4M | 471.9M | 492.2M | 538.6M |
| 2020 | 321.7M | 311.4M | 358.4M | 380.8M |
| 2019 | 261.8M | 278.5M | 296.4M | 307.0M |
| 2018 | 203.7M | 224.5M | 236.3M | 264.2M |
| 2017 | 90.3M | 122.5M | 141.3M | 174.1M |
| 2016 | 48.2M | 57.0M | 70.2M | 82.7M |
| 2015 | 23.5M | 28.6M | 36.7M | 36.8M |
| 2014 | 36.8M | 31.6M | 17.0M | 25.2M |
| 2013 | 28.6M | 27.8M | 36.9M | 34.7M |
| 2012 | 113.1M | 115.9M | 36.7M | 33.9M |
| 2011 | 0 | 0 | 0 | 105.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for PTCT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 06, 2023 | young alethia | sold | -464,972 | 39.857 | -11,666 | - |
| Sep 06, 2023 | young alethia | acquired | 324,898 | 27.85 | 11,666 | - |
| Jul 13, 2023 | gravier pierre | acquired | - | - | 26,000 | chief financial officer |
| Jun 07, 2023 | schmertzler michael | sold | -44,860 | 44.86 | -1,000 | - |
| Jun 06, 2023 | bell william f. jr. | acquired | - | - | 6,333 | - |
| May 23, 2023 | reeve emma | sold | -157,885 | 59.5342 | -2,652 | - |
| May 23, 2023 | reeve emma | acquired | 88,520 | 33.3786 | 2,652 | - |
| May 22, 2023 | reeve emma | acquired | 237,484 | 33.3733 | 7,116 | - |
| May 22, 2023 | reeve emma | sold | -423,630 | 59.5321 | -7,116 | - |
| May 22, 2023 | pauwels eric | sold | -118,791 | 59.0122 | -2,013 | chief business officer |
Which funds bought or sold PTCT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 07, 2023 | Hudson Bay Capital Management LP | new | - | 1,344,600 | 1,344,600 | -% |
| Dec 06, 2023 | CITIGROUP INC | added | 129 | 968,281 | 4,641,510 | -% |
| Nov 30, 2023 | Neo Ivy Capital Management | added | 2,437 | 245,000 | 264,000 | 0.12% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 15.88 | -474,185 | 837,708 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | sold off | -100 | -614,239 | - | -% |
| Nov 21, 2023 | Walleye Capital LLC | added | 958 | 1,337,470 | 1,614,190 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 7,059 | 7,059 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 10.21 | -16,269,800 | 25,159,700 | 0.15% |
| Nov 17, 2023 | Diversified Trust Co | added | 2.45 | -230,071 | 298,232 | 0.01% |
| Nov 17, 2023 | TimesSquare Capital Management, LLC | sold off | -100 | -23,278,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of PTC Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Nov 13, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Oct 30, 2023 | camber capital management lp | 5.31% | 2,013 | SC 13G | |
| Feb 14, 2023 | rtw investments, lp | 7.7% | 5,615,387 | SC 13G/A | |
| Feb 09, 2023 | janus henderson group plc | 2.8% | 2,027,142 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 10.21% | 7,339,520 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 10.34% | 7,430,907 | SC 13G/A | |
| Feb 01, 2023 | franklin resources inc | 4.8% | 3,489,687 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.2% | 6,640,854 | SC 13G/A | |
| Jul 11, 2022 | vanguard group inc | 10.07% | 7,183,692 | SC 13G/A |
Recent SEC filings of PTC Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 13, 2023 | SC 13G/A | Major Ownership Report | |
| Nov 07, 2023 | POSASR | POSASR | |
| Oct 30, 2023 | SC 13G | Major Ownership Report | |
| Oct 26, 2023 | 8-K | Current Report | |
| Oct 26, 2023 | 10-Q | Quarterly Report | |
| Oct 19, 2023 | 8-K | Current Report | |
| Oct 19, 2023 | 8-K | Current Report | |
| Sep 28, 2023 | 8-K | Current Report | |
| Sep 22, 2023 | 8-K | Current Report | |
| Sep 15, 2023 | 8-K | Current Report |
Peers (Alternatives to PTC Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
PTC Therapeutics Inc News
Latest updates
Financials for PTC Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -8.1% | 196,576,000 | 213,808,000 | 220,382,000 | 167,412,500 | 217,127,000 | 165,526,000 | 148,735,000 | 165,230,500 | 138,743,000 | 116,676,000 | 117,942,000 | 118,864,000 | 118,404,000 | 75,239,000 | 68,259,000 | 96,459,000 | 71,416,000 | 85,522,000 | 53,583,000 | 85,833,000 | 53,591,000 |
| Operating Expenses | -25.7% | 314,740,000 | 423,351,000 | 337,997,000 | 367,752,000 | 285,314,000 | 257,888,000 | 235,257,000 | 249,958,500 | 231,819,000 | 215,169,000 | 216,090,000 | 215,238,000 | 173,535,000 | 262,512,000 | 161,250,000 | 169,243,000 | 131,891,000 | 124,280,000 | 122,723,000 | 131,476,000 | 101,821,000 |
| S&GA Expenses | -8.6% | 80,886,000 | 88,449,000 | 86,914,000 | 92,717,500 | 80,118,000 | 79,892,000 | 73,271,000 | 86,548,000 | 69,252,000 | 68,878,000 | 61,095,000 | 75,456,000 | 57,840,000 | 53,659,000 | 58,209,000 | 63,497,500 | 49,284,000 | 49,215,000 | 40,544,000 | 48,666,000 | 38,368,000 |
| R&D Expenses | -11.7% | 164,212,000 | 185,874,000 | 195,124,000 | 188,693,500 | 165,462,000 | 157,263,000 | 140,078,000 | 149,844,000 | 130,845,000 | 125,482,000 | 134,513,000 | 118,013,000 | 92,998,000 | 176,525,000 | 90,107,000 | 81,831,000 | 63,076,000 | 59,979,000 | 52,566,000 | 53,646,500 | 54,368,000 |
| EBITDA Margin | - | - | - | -0.56 | -0.63 | -0.60 | -0.71 | -0.75 | -0.83 | -0.76 | -0.62 | -0.84 | -0.92 | -0.99 | -1.20 | -0.73 | -0.65 | - | - | - | - | - |
| Interest Expenses | 25.2% | 11,710,000 | 9,354,000 | 12,956,000 | 5,784,000 | 4,406,000 | 2,143,000 | 6,130,000 | -1,000 | 4,407,000 | - | 5,182,000 | - | 4,516,000 | 408,000 | 4,878,000 | 651,000 | 3,931,000 | - | 3,111,000 | 846,000 | 3,089,000 |
| Income Taxes | 12.9% | -33,620,000 | -38,596,000 | 3,969,000 | -18,804,000 | -17,893,000 | 3,392,000 | 4,835,000 | 4,657,500 | -36,000 | 488,000 | 451,000 | 12,634,000 | 22,288,000 | 84,000 | 222,000 | 10,644,000 | -344,000 | 774,000 | 576,000 | -993,500 | 355,000 |
| Earnings Before Taxes | 29.9% | -166,590,000 | -237,479,000 | -134,990,000 | -189,693,000 | -127,208,000 | -148,695,000 | -121,891,000 | -138,607,500 | -133,660,000 | -117,882,000 | -128,191,000 | -61,720,000 | -47,404,000 | -181,343,000 | -112,465,000 | -67,033,000 | -60,341,000 | -41,015,000 | -71,537,000 | -49,323,000 | -50,614,000 |
| EBT Margin | - | - | - | -0.78 | -0.84 | -0.77 | -0.88 | -0.90 | -0.96 | -0.90 | -0.75 | -0.97 | -1.06 | -1.14 | -1.35 | -0.87 | -0.78 | - | - | - | - | - |
| Net Income | 33.1% | -132,970,000 | -198,883,000 | -138,959,000 | -170,889,000 | -109,315,000 | -152,087,000 | -126,726,000 | -143,265,000 | -133,624,000 | -118,370,000 | -128,642,000 | -74,354,000 | -69,692,000 | -181,427,000 | -112,687,000 | -77,677,000 | -59,997,000 | -41,789,000 | -72,113,000 | -48,330,000 | -50,969,000 |
| Net Income Margin | - | - | - | -0.74 | -0.80 | -0.76 | -0.90 | -0.92 | -0.97 | -0.92 | -0.83 | -1.05 | -1.15 | -1.23 | -1.39 | -0.91 | -0.82 | - | - | - | - | - |
| Free Cashflow | - | - | - | -39,761,000 | -174,585,000 | -43,427,000 | -63,942,000 | -106,716,000 | -77,566,000 | -57,034,000 | -39,119,000 | -105,826,000 | -70,718,000 | 23,351,000 | -76,970,000 | -87,577,000 | -14,859,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -5.8% | 1,260 | 1,338 | 1,609 | 1,706 | 1,576 | 1,804 | 1,800 | 1,938 | 2,007 | 2,059 | 2,112 | 2,208 | 2,181 | 1,477 | 1,546 | 1,624 | 1,641 | 1,292 | 1,284 | 1,119 | 1,029 |
| Current Assets | -8.4% | 540 | 590 | 613 | 694 | 517 | 695 | 774 | 954 | 1,011 | 1,066 | 1,122 | 1,232 | 1,244 | 605 | 692 | 779 | 807 | 475 | 479 | 321 | 313 |
| Cash Equivalents | -20.7% | 165 | 208 | 167 | 280 | 121 | 174 | 152 | 197 | 197 | 185 | 154 | 216 | 441 | 166 | 131 | 296 | 531 | 136 | 201 | 169 | 207 |
| Inventory | 11.7% | 36.00 | 32.00 | 27.00 | 22.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 16.00 | 16.00 | 19.00 | 19.00 | 18.00 | 19.00 | 19.00 | 17.00 | 17.00 | 16.00 | 16.00 | 14.00 |
| Net PPE | 3.5% | 85.00 | 82.00 | 79.00 | 73.00 | 67.00 | 65.00 | 59.00 | 53.00 | 46.00 | 43.00 | 37.00 | 34.00 | 28.00 | 27.00 | 26.00 | 22.00 | 18.00 | 15.00 | 15.00 | 13.00 | 9.00 |
| Goodwill | 0% | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 100 |
| Liabilities | 0.7% | 1,931 | 1,917 | 2,066 | 2,053 | 1,803 | 1,986 | 1,890 | 1,937 | 1,902 | 1,862 | 1,819 | 1,726 | 1,670 | 904 | 1,017 | 1,029 | 978 | 803 | 771 | 768 | 643 |
| Current Liabilities | 3.3% | 492 | 476 | 442 | 406 | 420 | 567 | 477 | 509 | 465 | 291 | 251 | 277 | 254 | 202 | 218 | 236 | 184 | 174 | 143 | 167 | 115 |
| LT Debt, Current | - | - | - | - | - | - | 150 | 150 | 150 | 149 | - | - | - | - | 18.00 | 20.00 | 20.00 | 20.00 | 20.00 | 17.00 | 12.00 | 7.00 |
| LT Debt, Non Current | 0.1% | 573 | 573 | 572 | 572 | 283 | 282 | 282 | 282 | 282 | 430 | 430 | 309 | 303 | 297 | 295 | 294 | 293 | 136 | 138 | 141 | 144 |
| Shareholder's Equity | -15.8% | -670 | -579 | - | -347 | -226 | -182 | - | 1.00 | 105 | 197 | 293 | 482 | 511 | 572 | 529 | 594 | 664 | 489 | 513 | 351 | 386 |
| Retained Earnings | -4.4% | -3,127 | -2,994 | -2,795 | -2,656 | -2,486 | -2,376 | -2,224 | -2,097 | -1,954 | -1,821 | -1,702 | -1,628 | -1,554 | -1,484 | -1,303 | -1,190 | -1,112 | -1,052 | -1,011 | -938 | -890 |
| Additional Paid-In Capital | 1.3% | 2,447 | 2,417 | 2,340 | 2,305 | 2,223 | 2,184 | 2,153 | 2,124 | 2,093 | 2,064 | 2,034 | 2,172 | 2,101 | 2,067 | 1,834 | 1,795 | 1,776 | 1,540 | 1,523 | 1,288 | 1,275 |
| Shares Outstanding | 0.2% | 75.00 | 75.00 | 74.00 | 73.00 | 72.00 | 71.00 | 71.00 | 71.00 | 71.00 | 70.00 | 70.00 | 70.00 | 68.00 | 64.00 | 62.00 | 62.00 | 58.00 | 57.00 | 56.00 | 47.00 | 45.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -2.8% | -14.52 | -14.12 | -29.49 | -165 | -38.04 | -55.24 | -97.40 | -68.84 | -51.19 | -31.14 | -100 | -64.37 | 27.00 | -74.81 | -81.55 | -10.21 | -15.50 | -30.52 | -42.41 | -15.14 | 3.00 |
| Share Based Compensation | -8.3% | 27.00 | 29.00 | 29.00 | 27.00 | 29.00 | 28.00 | 27.00 | 26.00 | 26.00 | 26.00 | 26.00 | 21.00 | 17.00 | 17.00 | 15.00 | 11.00 | 10.00 | 11.00 | 9.00 | 8.00 | 9.00 |
| Cashflow From Investing | -24.6% | -29.60 | -23.75 | -28.97 | 32.00 | 136 | 72.00 | 49.00 | 68.00 | 65.00 | 56.00 | 30.00 | -208 | -394 | 142 | -101 | -229 | 30.00 | -38.17 | -150 | -24.60 | -24.11 |
| Cashflow From Financing | -81.8% | 3.00 | 18.00 | 4.00 | 303 | -139 | 4.00 | 1.00 | 4.00 | 3.00 | 4.00 | 10.00 | 40.00 | 643 | -32.92 | 18.00 | 2.00 | 382 | 3.00 | 226 | 4.00 | 5.00 |
PTCT Income Statement
2023-09-30Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenues: | ||||
| Revenue | $ 196,576 | $ 217,127 | $ 630,766 | $ 531,389 |
| Operating expenses: | ||||
| Cost of product sales, excluding amortization of acquired intangible assets | 9,493 | 14,011 | 36,368 | 33,785 |
| Amortization of intangible assets | 58,649 | 31,023 | 145,461 | 80,790 |
| Research and development | 164,212 | 165,462 | 545,210 | 462,802 |
| Selling, general and administrative | 80,886 | 80,118 | 256,249 | 233,280 |
| Change in the fair value of contingent consideration | 1,500 | (5,300) | (125,000) | (32,200) |
| Intangible asset impairment | 217,800 | |||
| Total operating expenses | 314,740 | 285,314 | 1,076,088 | 778,457 |
| Loss from operations | (118,164) | (68,187) | (445,322) | (247,068) |
| Interest expense, net | (28,160) | (20,880) | (84,905) | (66,371) |
| Other expense, net | (20,266) | (38,141) | (8,832) | (84,355) |
| Loss before income tax benefit | (166,590) | (127,208) | (539,059) | (397,794) |
| Income tax benefit | 33,620 | 17,893 | 68,247 | 9,666 |
| Net loss attributable to common stockholders | $ (132,970) | $ (109,315) | $ (470,812) | $ (388,128) |
| Weighted-average shares outstanding: | ||||
| Basic | 75,377,997 | 71,654,671 | 74,618,611 | 71,415,849 |
| Diluted | 75,377,997 | 71,654,671 | 74,618,611 | 71,415,849 |
| Net loss per share-basic and diluted (in dollars per share) | ||||
| Basic | $ (1.76) | $ (1.53) | $ (6.31) | $ (5.43) |
| Diluted | $ (1.76) | $ (1.53) | $ (6.31) | $ (5.43) |
| Net product revenue | ||||
| Revenues: | ||||
| Revenue | $ 144,038 | $ 134,186 | $ 506,187 | $ 407,720 |
| Collaboration revenue | ||||
| Revenues: | ||||
| Revenue | 0 | 50,017 | 6 | 50,024 |
| Royalty revenue | ||||
| Revenues: | ||||
| Revenue | 50,173 | 32,924 | 117,857 | 73,645 |
| Manufacturing revenue | ||||
| Revenues: | ||||
| Revenue | $ 2,365 | $ 0 | $ 6,716 | $ 0 |
PTCT Balance Sheet
2023-09-30Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 165,157 | $ 279,834 |
| Marketable securities | 129,653 | 130,871 |
| Trade and royalty receivables, net | 165,718 | 155,614 |
| Inventory, net | 35,752 | 21,808 |
| Prepaid expenses and other current assets | 44,082 | 105,658 |
| Total current assets | 540,362 | 693,785 |
| Fixed assets, net | 85,031 | 72,590 |
| Intangible assets, net | 423,342 | 705,891 |
| Goodwill | 82,341 | 82,341 |
| Operating lease ROU assets | 94,072 | 102,430 |
| Deposits and other assets | 34,737 | 48,582 |
| Total assets | 1,259,885 | 1,705,619 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 370,731 | 320,366 |
| Deferred revenue | 1,224 | 1,351 |
| Operating lease liabilities- current | 11,703 | 9,370 |
| Finance lease liabilities- current | 2,611 | 3,000 |
| Liability for sale of future royalties - current | 105,849 | 72,149 |
| Total current liabilities | 492,118 | 406,236 |
| Long-term debt | 573,174 | 571,722 |
| Contingent consideration payable | 39,000 | 164,000 |
| Deferred tax liability | 51,927 | 102,834 |
| Operating lease liabilities- noncurrent | 99,682 | 100,860 |
| Finance lease liabilities- noncurrent | 17,184 | 18,675 |
| Liability for sale of future royalties- noncurrent | 657,469 | 685,737 |
| Other long-term liabilities | 141 | 2,641 |
| Total liabilities | 1,930,695 | 2,052,705 |
| Stockholders' deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,459,022 shares at September 30, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022 | 75 | 72 |
| Additional paid-in capital | 2,447,292 | 2,305,020 |
| Accumulated other comprehensive income | 9,609 | 4,796 |
| Accumulated deficit | (3,127,786) | (2,656,974) |
| Total stockholders' deficit | (670,810) | (347,086) |
| Total liabilities and stockholders' deficit | $ 1,259,885 | $ 1,705,619 |
| CEO | Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS |
|---|---|
| WEBSITE | www.ptcbio.com |
| EMPLOYEES | 1402 |